← All trials
NCT06867406
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 7, 2025
- Primary completion
- Nov 30, 2025
- Completion date
- Jan 31, 2026
- First posted
- Mar 10, 2025
- Last posted
- Mar 10, 2025
- Enrollment
- 92
- Arms / groups
- 12 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kunming Pharmaceuticals, Inc.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.